Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.23.1
Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Net sales $ 294,146 $ 290,376   $ 835,382 $ 817,371  
Operating income 80,211 90,447   204,419 216,017  
Costs recognized on sale of acquired inventory       (400) (1,596)  
Impact of partially owned consolidated subsidiaries(1)   595   (179) 9,343  
Eminence impairment         (18,715)  
Corporate general, selling, and administrative expenses (99,238) (89,269)   (291,624) (276,137)  
Total intangible assets, net 553,257     553,257   $ 531,522
Diagnostics and Genomics [Member]            
Restructuring costs     $ (1,185)     $ (242)
Operating Segments [Member]            
Operating income 110,220 116,155   302,434 317,879  
Costs recognized on sale of acquired inventory       (400) (1,596)  
Amortization of acquisition related intangible assets (19,286) (18,173)   (57,694) (54,942)  
Impact of partially owned consolidated subsidiaries(1)   (892)   647 (3,446)  
Acquisition related expenses and other 1,333 3,710   9,343 19,328  
Eminence impairment         (18,715)  
Stock based compensation, inclusive of employer taxes (10,543) (9,056)   (42,879) (37,731)  
Restructuring costs   291   (2,950) (1,638)  
Operating Segments [Member] | Protein Sciences [Member]            
Net sales 218,903 213,176   622,739 615,332  
Operating income 98,756 96,750   274,035 280,131  
Operating Segments [Member] | Diagnostics and Genomics [Member]            
Net sales 75,669 77,679   213,577 203,191  
Operating income 11,464 19,405   28,399 37,748  
Intersegment Eliminations [Member]            
Net sales (426) (479)   (934) (1,152)  
Corporate, Non-Segment [Member]            
Corporate general, selling, and administrative expenses $ (1,513) $ (1,588)   $ (4,082) $ (3,122)